Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 970 in its research report ...

Ahmedabad-based Zydus Lifesciences Ltd has registered a decline of around 1% in net profit at Rs. 1,170.9 crore during the last quarter of FY25, as compared to Rs. 1,182.3 crore in the same period a ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...

Zydus Lifesciences Ltd. reported growth in the fourth quarter of fiscal 2025, driven by higher non-recurring components in ...

Shares of Hindalco, EIH, Zydus Lifesciences and Dixon Technologies will remain in focus as companies are set to post their Q4 ...

Results: Zydus Lifesciences Q4FY25 net profit dips 1% to Rs 1,244 crore due to exceptional charge; revenue grows 17% to Rs ...

Zydus Lifesciences Limited reported a significant 19% increase in revenue for FY25, reaching Rs. 2,32,415 million. The ...

Zydus Lifesciences Limited announced a notable 19% increase in revenue for FY25, with net profits rising to Rs. 47,451 mn.

At least 142 companies, including Religare Enterprises, NHPC and Zydus Lifesciences, are scheduled to announce financial ...

This came after Zydus Lifesciences presented the proposal for a grant of permission to manufacture and market Aprepitant ...

India's Gland Pharma, which make injectable versions of generic drugs, reported a 3.1% fall in fourth-quarter profit on Tuesday, weighed down by weaker sales in the U.S., a key region for the company.

Consolidated revenue from operations rose 18% YoY to Rs 6528 crore, while EBITDA surged 30% to Rs 2,126 crore, with margins ...